Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer

Platinum chemotherapy remains the cornerstone of treatment for epithelial ovarian cancer (OC) and Poly (ADP-ribose) polymerase inhibitors (PARPi) now have an established role as maintenance therapy. The mechanisms of action of these agents is, in many ways, complementary, and crucially reliant on th...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Michelle McMullen, Katherine Karakasis, Ainhoa Madariaga, Amit M. Oza
Formato: Artigo
Idioma:Inglês
Publicado: MDPI AG 2020-06-01
Series:Cancers
Assuntos:
resistance mechanisms
platinum
PARP
ovarian cancer
homologous recombination
Acceso en liña:https://www.mdpi.com/2072-6694/12/6/1607
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares